CD274 and neoplasm: Regardless of PD‐L1 expression, CheckMate 227, an international phase III trial of nivolumab and ipilimumab, showed benefits of immunotherapy in patients with NSCLC who had a high tumor mutation burden.20 Therefore, it was suggested that we could not select patients effectively by using only PD‐L1 expression.